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IMPROVEMENT OF 
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comparing intraoperative 
high versus low mean 
arterial pressure 
Background The objective of this randomized clinical trial of elective coronary 
artery bypass grafting was to investigate whether intraoperative mean arterial 
pressure below autoregulatory limits of the coronary and cerebral circulations 
was a principal determinant of postoperative complications. The trial com- 
pared the impact of two strategies of hemodynamic management during 
cardiopulmonary b pass on outcome. Patients were randomized to a low mean 
arterial pressure of 50 to 60 mm Hg or a high mean arterial pressure of 80 to 
100 mm Hg during cardiopulmonary b pass. Methods A total of 248 patients 
undergoing primary, nonemergency coronary bypass were randomized to 
either low (n = 124) or high (n = 124) mean arterial pressure during 
cardiopulmonary b pass. The impact of the mean arterial pressure strategies 
on the following outcomes was assessed: mortality, cardiac morbidity, neuro- 
logic morbidity, cognitive deterioration, and changes in quality of life. All 
patients were observed prospectively to 6 months after the operation. Results 
The overall incidence of combined cardiac and neurologic complications wa  
significantly lower in the high pressure group at 4.8% than in the low pressure 
group at 12.9% (p = 0.026). For each of the individual outcomes, the trend 
favored the high pressure group. At 6 months after coronary bypass for the 
high and low pressure groups, respectively, total mortality rate was 1.6% versus 
4.0%, stroke rate 2.4% versus 7.2%, and cardiac complication rate 2.4% versus 
4.8%. Cognitive and functional status outcomes did not differ between the 
groups. Conclusion Higher mean arterial pressures during cardiopulmonary 
bypass can be achieved in a technically safe manner and effectively improve 
outcomes after coronary bypass. (J THORAC CARDIOVASC SURG 1995;110: 
1302-14) 
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C oronary artery bypass grafting (CABG) prolongs life among patients with severe triple vessel or 
left main coronary artery disease. 1' 2 Refinements in 
surgical and anesthetic techniques over the past 
decade have significantly reduced the risk of post- 
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operative cardiac morbidity. 3'4 The incidence of 
neurologic complications, however, has not de- 
creased significantly. 5' 6 
Efforts to understand the pathophysiology of neu- 
rologic and cognitive injury 7'8 have focused on 
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intraoperative issues unique to cardiac surgery, such 
as type of oxygenators, 9 size and types of arterial 
filters, 1° and anesthetic techniques during cardiopul- 
monary bypass (CPB). Hemodynamic patterns dur- 
ing CABG, especially mean arterial pressures 
(MAPs) and fixed flow rates, have received less 
attention. 11 Our hypothesis was that intraoperative 
MAP below the autoregulatory limits of the coro- 
nary and cerebral circulations may be a principal 
determinant of postoperative complications. There- 
fore. patients maintained at higher MAPs would 
have better outcomes. 
The objective of this trial was to compare the 
impact of two strategies of hemodynamic manage- 
ment during CPB on outcome. Patients were ran- 
domized to an MAP of either 50 to 60 mm Hg (usual 
range) or 80 to 100 mm Hg (intervention group). 
The impact of the MAP strategies on outcomes of 
mortality, cardiac morbidity, neurologic morbidity, 
cognitive deterioration, and changes in quality of life 
were assessed. 
Methods 
Patient eligibility. Between October 1991 and Febru- 
ary 1994. patients undergomg primary elective multivessel 
CABG for left mare or multivessel coronary artery disease 
at The New York Hospital-Cornell Medical Center were 
eligible for enrollment. Exclusion criteria included inabil- 
ity to complete the neuropsychologic tests (blindness, 
deafness, language difficulties), participation in other 
studies, and inability to return for follow-up. A total of 423 
eligible patients were identified. Two-hundred fifty-one 
patients agreed to participate. All patients gave informed 
written consent per institutional review board guidelines. 
Baseline evaluation. Cardiac and neurologic status, co- 
morbidity, 12 depression (assessed by the CES-D13), and 
physical examination were documented. Cognitive func- 
tion 14 was assessed with an eleven-test neuropsychologic 
battery (WAIS-R Digit Span, Trail Making A and B, 
Boston Naming, Benton Visual Retention and Recogni- 
tion Test, Controlled Oral Word Association, WAIS-R 
Digit Symbol, Mattis-Kovner Verbal Recall and Recogni- 
tion, and Finger Tapping Test) evaluating memory (recall 
and recognition), linguistic, attention, and psychomotor 
functions, The Ammons Quick Test 15 was used as a proxy 
for verbal intelligence quotient. Quality of life was mea- 
sured by the SF-36 Health Survey, which evaluates even 
functional domains: physical, social, role, energy, mental, 
pain, and general health. 16 
Randomization procedure and treatment protocol. 
Randomization was based on a table of random numbers. 
On entrance into the operating room, patients were 
randomized to either low or high MAP during CPB. In the 
low MAP (control) group, MAP during CPB was main- 
tained between 50 and 60 mm Hg, and in the high MAP 
(experimental) group, between 80 and 100 mm Hg. In 
both groups, CPB flow by body surface area andtemper- 
ature were held constant, and vasoactive drugs were used 
to maintain MAP in the desired range. Three patients 
were dropped from the trial. One of these patients did not 
undergo CABG because of severe aortic calcification and 
two patients required valve replacement, as detected by 
transesophageal echocardiography at the time of the 
operation. Initially, CABG reoperation was not an exclu- 
sion and one patient undergoing reoperation was en- 
rolled. Patients undergoing reoperation were subse- 
quently excluded. 
Intraoperative monitoring. All hemodynamic parame- 
ters including blood pressure, heart rate, temperature, 
and pulmonary artery pressures were downloaded every 
10 seconds from a Marquette 7000 monitor (Marquette, 
Milwaukee, Wis.). All operative events, pharmacologic 
agents, and bypass parameters were recorded on:line by a 
research assistant using a locally developed program 
synchronized with Marquette downloading. Anesthesia 
was induced with thiopental (1 to 2 mg/kg) and fentanyl 
(25 /xg/kg). Pancuronium provided muscle relaxationl 
Anesthesia was maintained with a fentanyl bolus (1 to 
5 /xg/kg, to a total of 50 to 70 /xg/kg), midazolam, or 
isoflurane (pre-CPB and post-CPB periods only). After 
sternotomy and pericardial incision, heparin was admin- 
istered to maintain an activated clotting time of more than 
480 seconds. After cannulation of the aorta and right 
atrium, nonpulsatile CPB with a membrane oxygenator 
and a 40 /xm blood filter (Pall Biomedical, East Hills, 
N.Y.) was instituted. A Bio-Medicus centrifugal pump 
(Medtronic Bio-Medicus, Eden Prairie, Minn.) or a roller 
pump (Cobe Cardiovascular Inc., Arvada, Colo.) was used 
as available. Flow rates were set at 1.6 and 2.4 L/min per 
square meter during cooling and warming, respectively. 
The alpha-stat protocol 17 for blood ga s management was 
used, and body temperature was cooled to 28 ° to 30 ° C. 
Combinations of antegrade and retrograde cold blood 
cardioplegia were used with a potassium concentration of
28 mEq/L. If the MAP increased above the target level 
and was unresponsive to fentanyl or midazolam, sodium 
nitroprusside infusion was administered. If the MAP fell 
below the target level, phenylephrine was used. If neces- 
sary, norepinephrine or metaraminol was added. Intra0p- 
erative ischemia was managed by an identical algorithm in 
both groups (Appendix 1). 
Follow-up. The study cardiologist and neurologist, 
blinded to the intraoperative management, performed 
standardized examinations at 1, 2, and 7 days after the 
operation and at 6 months. The neuropsychol0gic bat- 
tery was administered on postoperative day 7 and at 6 
months. At 6 months, an interval history including the 
patient's symptoms, medications, and hospitalizations 
was obtained, and the SF-36 and CES-D tests were 
readministered. 
Definitions of trial outcomes. The outcomes assessed at 
6 months were mortality, cardiac morbidity, neurologic 
morbidity, deterioration i  cognitive status, and deterio- 
ration in quality of life. All deaths before 6 months were 
counted. Cardiac complications were myocardial infarc- 
tion, pulmonary edema, adult respiratory distress syn- 
drome, low flow state/cardiogenic shock, and cardiopul- 
monary arrest (Appendix 2). Final designation of cardiac 
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Table I. Baseline comparability of the two 
MAP groups* 
Low MAP High MAP 
(n = 124) (n = 124) 
Demographic 
Age (yr, mean _+ SD) 66.2 + 10.1 65.4 _+ 8.6 
Male 78 82 
Caucasian 91 95 
Widowed 15 11 
High school education 93 87 
or higher 
Working 44 56 
Cardiac and neurologic history 
Symptom duration 5.4 + 7.7 5.0 _+ 7.3 
(yr, mean _+ SD) 
Previous angioplasty 6 10 
No angina 14 27 
Canadian Cardiovascular 
Society class 
I 19 16 
II 25 23 
III 15 11 
IV 27 23 
Ejection fraction 48.8 _+ 12.7 47.6 _+ 12.3 
(%, mean _+ SD) 
Left main disease 16 10 
Previous myocardial 38 48 
infarction 
Congestive failure 9 6 
Valvular disease 5 3 
(aortic or mitral) 
Previous troke 5 6 
Comorbidity 
Comorbidity score 
0-i 56 59 
2-3 32 28 
>--4 12 13 
Body surface area (m 2, mean _+ SD) 1.9 +_ 0.2 1.9 _+ 0.2 
Hypertension 44 56 
Diabetes 23 18 
Renal dysfunction 3 5 
Cancer 11 12 
COPD or asthma 6 13 
Cigarette smoking 
Never 27 25 
Former 59 61 
Current 9 3 
Medications 
Diuretics 20 18 
Calcium channel blockers 60 66 
Beta blockers 54 59 
Nitrates 63 46 
Aspirin 51 52 
Antihypertensives 19 15 
COPD, Chronic obstructive pulmonary disease; SD, standard eviation. 
*Each entry is given in percent unless otherwise specified. 
complications was determined by agreement of two car- 
diologists blinded to the protocol. 
Definite stroke was the principal neurologic omplication 
determined by the neurologist. Stroke included the new 
onset of a localized and persistent neurologic deficit (e.g., 
paresis, plegia, aphasia, hemianopsia, cortical blindness). 
Deterioration on three or more cognitive tests was 
defined as a cognitive complication. For each test, the 
assessment was based on within-patient change in test 
performance from preoperative baseline. Changes from 
preoperative to postoperative function that would be 
considered clinically important were determined a priori 
by a panel of experts (Appendix 3). Deterioration in 
quality of life was defined as a decline of more than five 
points on the physical component summary score of the 
SF-36) 8 
Statistical analysis. Baseline characteristics and trial 
outcomes in the two groups were compared by means of 
an intention-to-treat analysis. Subsequently, a pragmatic 
analysis (based on achieved MAP) was performed in 
which the frequency of outcomes was examined by the 
actual MAP achieved, regardless of randomization group. 
Either the )(2 or Fisher's exact test was used to compare 
the proportions in the two groups. Confidence intervals 
were also used to assess the overall difference between the 
two groups. Logistic regression was used to ensure that 
differences in baseline clinical characteristics or intraop- 
erative management did not confound the results. 
Results 
Comparability of treatment groups. A total of 
124 patients were randomized to each treatment 
arm. Baseline characteristics for the two groups are 
shown in Table I. The mean age was 65.8 _+ 9.4 
years, and 80% were male. Approx imate ly  50% 
were college graduates and 50% were working be- 
fore the operation. Hal f  had a history of hyperten- 
sion, 43% a previous myocardial  infarction, and 8% 
previous angioplasty. The preoperat ive MAP,  an 
average of the three most recent b lood pressures 
recorded before entrance into the operat ing room, 
was 81 mm Hg in both groups. The angiographical ly 
determined mean ejection fraction was 48%, and 
13% had left main disease. A l though 20% of pa- 
tients had no chest pain, 37% had Canadian Car- 
diovascular Society class I I I  or IV ang ina)  9 Six 
percent of patients reported a previous stroke. The 
two MAP groups were similar with regard to demo- 
graphic and clinical characteristics. However,  pa- 
tients in the high MAP group were more likely to be 
working (p = 0.042) and angina-free (p = 0.008) 
before the operat ion,  whereas those in the low MAP 
group were more often taking prescr ipt ion itrates 
before the operat ion (p = 0.007). 
Table I I  shows the 11 preoperat ive neuropsycho- 
logic test scores for the two t reatment  groups. There 
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were no significant differences inbaseline test scores 
for any test, including verbal intelligence quotient. 
The preoperative scores for the domains of the 
SF-36 are shown in Fig. 1. There were no significant 
differences in domain or summary scores between 
the treatment groups. The physical component sum- 
mary score was 40.5 _+ 9.9 in the low MAP and 
42.2 _+ 11.2 in the high MAP group. 
The details of the management of the two groups 
during the operative period are shown in Table IIIa. 
The durations of CPB and of crossclamp and side- 
biter clamp application were comparable. Patients 
in the low MAP group received an average of 3.1 
bypass grafts versus 2.9 in the high MAP group, and 
80% of  patients received an internal mammary 
graft. A centrifugal pump during CPB was used in 
more of the patients in the high MAP group (84.7% 
versus 72.6%, p = 0.02). Flows during CPB normal- 
ized for body surface area were identical in the two 
groups. The mean blood temperature achieved after 
systemic cooling was 28.4 °C in the low MAP group 
and 28.5 °C in the high MAP group. 
The target blood pressures of 50 to 60 mm Hg for 
the low MAP and 80 to 100 mm Hg for the high 
MAP group corresponded to the MAP achieved at 
full flowi However, during CPB, there are episodes 
of low flow (typically lasting 30 to 60 seconds) 
necessitated by surgical technique (e.g., when the 
heart was retracted for examination of the distal 
vessels or to visualize anastomotic sites obscured by 
collateral bleeding). During CPB at full flow, an 
MAP o~ 59 _+ 5 mm Hg was achieved in the low 
MAP group and an MAP of 82 _+ 8 mm Hg in the 
high MAP group (p = 0.0001). During CPB, includ- 
ing all brief periods of low flow, the mean MAP was 
52 _+ 5 mm Hg for the low MAP group and 69 _+ 7 
mm Hg for the high MAP group. 
Management during CPB required that patients 
in both groups receive similar drugs, but in different 
dosages [Table IIIb). The high MAP group received 
significantly higher mean doses of phenylephrine 
(the first-line vasopressor) than did the low MAP 
group (p = 0.0001). Few patients in either group 
received the second-line vasopressors--epineph- 
rine, norepinephrine, or metaraminol. Thirty-six 
percent of the low MAP group and 4% of the high 
MAP group received sodium nitroprusside (the 
first-line i vasodilator), with patients in the low MAP 
group receiving significantly higher mean doses. The 
low MNP group also received significantly higher 
mean doses of nitroglycerin and fentanyl (Bonfer- 
roni, p < 0.0001 for all). 
Table II. Preoperative neuropsychologic test scores 
Low MAP High MAP 
Mean SD Mean SD 
Ammons IQ 105.7 14.8 105.4 13.2 
Linguistic function 
Boston Naming Test 24.6 4.4 24.6 4.6 
Controlled Oral Word 37.5 13.1 37.6 13.4 
Association 
Memory 
Benton Recall correct 5.3 2.1 4.9 2.4 
Benton Recognition 7.8 1.7 7.6 1.8 
Mattis-Kovner Verbal Recall 10.6 3.5 10.5 3.4 
Mattis-Kovner Recognition 2.7 0.8 2.7 0.7 
Psychomotor function 
Trails A 43.7 22.3 45.2 24.7 
Trails B 104.6 60.8 102.6 49.3 
Digit Symbol 40.9 13.7 41.4 10.7 
Digit Span 14.8 3.9 14.2 4.0 
Finger Tapping Test (dominant) 46.6 10.3 46.2 10.1 
SD, Standard eviation; IQ, intelligence quotient. 
Overall, 93% of the low and 91% of the high 
MAP group received vasopressors, and 79% of the 
low and 48% of the high MAP group received 
vasodilators. There was no relationship between the 
doses of vasoactive drugs and major cardiac or 
neurologic outcomes. 
Trial outcomes. At 6 months, the attrition rate 
was 4% (11/248 patients). In the low MAP group, 
three patients refused follow-up, one was lost to 
follow-up, and one moved. In the high MAP group, 
four patients refused follow-up and two patients 
moved. 
The major outcomes are mortality, cardiac mor- 
bidity, permanent eurologic deficit, cognitive com- 
plications, and deterioration i quality of life. For 
the 248 patients, the total mortality rate at 6 months 
was 4% in the low MAP and 1.6% in the high MAP 
group (p = 0.25). In the low MAP group, three 
patients (2.4%) died of cardiac or neurologic om- 
plications during hospitalization, and by 6 months 
two additional deaths (multisystem failure, lung 
cancer) were reported. In the high MAP group, two 
patients (1.6%) died of cardiac omplications after 
the operation, and there were no additional deaths 
by 6 months (Table IV). 
The overall incidence of major cardiac and neu- 
rologic outcomes was 12.9% in the low MAP and 
4.8% in the high MAP group (p = 0.026); the 
difference of 8.1% had a 95% confidence interval 
from 1.0% to 15.1%. Neither the differences in 
baseline characteristics (work status, freedom from 
angina, need for nitrates) nor the difference in type 
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Fig. 1. Preoperative scores for the seven domains of the SF-36 in the high and low MAP groups. 
of CPB pump used could explain these cardiac and 
neurologic outcomes. Stroke was more common in 
the low MAP group than in the high MAP group 
(7.2% versus 2.4%, p = 0.076). Cardiac complica- 
tions were also more common in the low MAP 
group (4.8% versus 2.4%, p = 0.3). Thus all differ- 
ences in mortality, cardiac morbidity, and neuro- 
logic morbidity favored the high MAP group. 
Congestive heart failure (i.e., $3 gallop, typical 
radiographic changes) occurred after the operation 
among 1.2.% of the low.MAP and 1.6% of the high 
MAP group without major cardiac events. Minor 
neurologic omplications were defined as focal cen- 
tral nervous system deficits lasting less than 24 
hours, including transient ischemic attacks, amauro- 
sis fugax, or transient monocular blindness in pa- 
tients without a new major focal deficit. In total, 
3.2% of the low and 0.8% of the high MAP group 
sustained a minor neurologic omplication. Differ- 
ences in minor complications also favored the high 
MAP group. 
Cognitive outcome was assessed by within-patient 
differences on the eleven-test battery. In total, 23 
patients (9.3%) did not complete testing at 6 
months: 11 were in the low MAP and 12 in the high 
MAP group (7 patients had died, 2 patients had a 
neurologic complication and could not complete 
testing, 3 patients refused, and 11 were lost to 
follow-up). Of those completing testing, 12% of the 
patients in the low and 11% of patients in the high 
MAP group demonstrated a clinically important 
decline on three or more tests (95% confidence 
interval for difference in deterioration i cognitive 
function between the two groups: -7.6% to 9.1%). 
Table V shows the mean within-patient change in 
scores from before to after operation for each 
neuropsychologic test for the two groups. There was 
no difference in change in score on any test except 
the Finger Tapper test (p = 0.05) between the two 
MAP groups. Thus the low and high MAP groups 
did not differ significantly with regard to preserva- 
tion of cognitive function. 
Fig. 2 shows the change in score for each of the 
seven domains of the SF-36. Change in functional 
status could not be assessed for 15 patients in each 
group (7 patients died, 11 patients were lost to 
follow-up, 2 patients had a neurologic event, and 10 
patients did not complete the SF-36 before or after 
the operation). The majority of patients demon- 
strated significant improvement in all seven do- 
mains. The degree of improvement did not differ 
between the groups: 8.3% of patients in the low 
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Table Ilia. Intraoperative management for the two treatment groups 
Low MAP High MAP 
Mean SD Mean SD 
Premedications 
Lorazepam (mg) 2.4 1.0 2.5 1.0 
Morphine (rag) 7.2 1.9 7.3 1.7 
Induction medications 
Fentanyl (/xg/kg) 40.1 20.0 40.1 14.0 
ThiopentaI (mg/kg) 1.2 1.5 1.4 1.4 
Heparin (units/kg) 315.4 92.0 306.6 92.6 
Midazolam (mg) 5.8 3.3 6.3 4.4 
Pancuronium (rag) 14.3 22.1 12.6 6.0 
Pre-CPB cardiac output (L/min) 3.5 1.5 3.6 1.5 
CPB time 
CPB duration (rain) 89.4 31.5 84.9 28.3 
Aortic crossclamp duration (rain) 46.7 20.0 43.1 16.7 
No. of grafts 3.1 0.8 2.9 0.8 
Internal mammary graft (%) 77.4 3.8 80.7 3.5 
Pump flows (L/min/m 2) 
CPB on--warming 1.9 0.3 1.9 0.3 
Warming--crossclamp off 2.0 0.3 1.9 0.3 
Crossclamp off--CPB off 2.3 0.2 2.2 0.3 
MAPs (ram Hg) 
CPB (full flow) 59.2 5.4 81.8 7.8 
CPB (for all flows) 51.8 5.2 69.5 7.1 
AOrtic crossclamp on (full flow) 56.5 7.1 81.2 7.8 
Aortic sidebiter clamp on (for all flows) 49.6 5.8 67.1 8.8 
No. of low flow intervals 7.7 3.2 9.3 3.8 
Hematocrit during CPB (%) 20.5 2.6 20.9 3.1 
Retfirned to CPB (%) 1.6 1.1 2.5 1.4 
SD, Standard eviation. 
Table IIIb. Medications during CPB 
Low MAP 
Mean dose 
per treated 
Medications during CPB patient SD 
High MAP 
Mean dose 
per treated 
No. patient SD No. 
Fentanyl (/,g/kg) 23.1 14.2 
Nitroglycerin (/,g) 1312.4 2801.3 
Midazolam (mg) 6.7 3.7 
Phenylephrine (mg) 2.4 2.1 
Epinephrine (/xg) 31.8 31.9 
Norepinephrine (/,g) 25.0 7.1 
Metaraminol (mg) 4.0 0 
Pancuronium (rag) 8.7 3.1 
117 15.1 9.5 104 
78 558.5 509.4 59 
106 5.4 4.7 97 
111 5.2 4.8 112 
28 52.2 68.0 18 
2 1525.0 1025.3 2 
1 5.1 2.3 6 
81 8.3 3.7 77 
SD, Standard eviation. 
MAP and 6.5% in the high MAP group reported a 
decline of more than five points in the physical 
component summary score. The 95% confidence 
interval for the difference in deterioration in func- 
tional status between the two groups was from 
-5.0% to 8.6%. 
A pragmatic analysis was conducted to ascertain 
whether the extent of compliance with the target 
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Table IV. Cardiac and neurologic outcomes in the two treatment groups (intention to treat) 
Low MAP High MAP 
(n = 124) (n = 124) 
No. % No. % No. 
Low - high MAP 
95% e l  for 
% % difference 
Fatal stroke 2 1.6 0 0.0 
Hemiparesis* 2 1.6 1 0.8 
Aphasia 3 2.4 1 0.8 
Cortical blindness 1 0.8 0 0.0 
Monocular blindness 1 0.8 0 0.0 
Other focal deficit 0 0.0 1 0.8 
Total permanent neurologic omplications 9 7.2 3 2.4 6 4.8 
Fatal cardiogenic shock 1 0.8 2 1.6 
Shock 1 0.8 0 0.0 
Myocardial infarction 4 3.2 1 0.8 
Total cardiac complications 6 4.8 3 2.4 3 2.4 
Other death, total (not attributable to 2 1.6 0 0 2 1.6 
cardiac or neurologic auses) 
Total mortality and major cardiac and 16t 12.9 6 4.8 10 8.1 
neurologic morbidity 
-0.5, 11.0 
-2.2, 7.1 
0.6, 3.8 
1.0, 15.1 
The last column shows the 95% confidence interval (CI) for the low MAP group percent minus high MAP group percent. 
*Hemiparesis and aphasia; hemiparesis, apraxia, and hemianopsia; hemiparesis, aphasia, and hemisensory deficit. 
tOne patient had both a cardiac and a neurologic omplication. 
Table V. Cognitive function 6 months after the 
operation: Mean within-patient change in score* 
Low MAP High MAP 
Mean SD Mean SD 
Linguistic function 
Boston Naming Test 0.4 2.0 0.8 2.3 
Controlled Word Association 0.0 8.3 0.6 6.1 
Memory 
Benton Visual Recall 0.5 1.9 0.8 1.9 
Benton Recognition 0.1 2.2 0.1 2.0 
Mattis-Kovner Recall 1.1 3.4 1.3 3.6 
Mattis-Kovner Recognition 0.08 0.79 0.11 0.72 
Psychomotor function 
Trails A -2 .7 15.4 -4.0 20.3 
Trails B -3 .6 46.9 -13.9 39.3 
Digit Symbol 2.5 5.9 3.7 6.7 
Digit Span 0.0 3.1 0.4 2.9 
Finger Tapping Test -1 .4  9.3 0.9 7.0 
SD, Standard eviation. 
*Score 6 months after the operation minus the preoperative score. 
blood pressure range affected the results. As shown 
in Table VI, patients in whom higher pressures were 
achieved had lower complication rates (p = 0.02). 
Table VI I  shows that there were no technical com- 
plications related to the MAP strategy; there was no 
increase in bleeding, transfusion requirements, or 
length of stay in the intensive care unit for patients 
in the high versus low MAP group. 
Discussion 
Previous trials in adults undergoing cardiac oper- 
ations for acquired disease have assessed the impact 
of different anesthetic agents (halothane, enflurane, 
isoflurane, and sufentanil), 2°-22 pH management, 17 
barbiturate infusions during CPB, 23' 24 filters,25, a6 
and oxygenators 9 on outcome after CABG and have 
not demonstrated significant differences in neuro- 
logic or cardiac complications. 
Historically, MAP during CPB has been main- 
tained in the range of 50 mm Hg, 11 and several 
studies have suggested that there was no adverse 
impact at this MAPY' 28 Several studies in noncar- 
diac operations have pointed to the importance of 
maintaining pressure within the autoregulatory 
range of the patient. 29 This trial is the first to 
address the issue of blood pressure management 
during CPB in patients having CABG. 
The physiology of autoregulation in the coronary 
and cerebral circulations is fundamental to the 
hypothesis that intraoperative blood pressure is 
related to the risk of complications. In the coronary 
and cerebral circulations, autoregulation preserves 
perfusion within a relatively narrow range. 3°' 31 Sys- 
temic pressures outside the limits of autoregulation 
may produce changes in perfusion with subsequent 
tissue damage. Our hypothesis is that patients whose 
MAP is maintained at higher pressures closer to 
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Fig. 2. Within patient change in SF-36 for the seven domains of the SF-36 for the high and low 
randomization groups. 
Table VI. Events' up to 6 months after the operation stratified by actual MAP achieved uring CPB 
(pragmatic analysis) 
Actual MAP achieved (ram Hg) 
<40 40-49 50-59 60-69 70- 79 >80 Total 
No. of patients 5 36 
All cardiac complications 20% 3% 
All neur01ogic complications 0% 3% 
All othe r deaths, (not attributable to 0% 3% 
cardiac or neurologic auses) 
Combined mortality and major cardiac 20% 8% 
and neurologic morbidity 
90 54 57 6 248 
7% 0% 2% 0% 9% 
10% 2% 2% 0% 12% 
1% 0% 0% 0% 2% 
17% 2% 4% 0% 22% 
Each entry is percent of patients in each MAP group who had a complication. 
their autoregulatory range will have decreased post- 
operative morbidity and deterioration i quality of 
life after CABG. 
There was prior evidence that MAP can be in- 
creased to achieve higher perfusion pressures in a 
manner that is technically safe while maintaining 
desirable patient outcomes. 32This has been con- 
firmed in l~he present rial. In this cohort, maintain- 
ing higher MAPs did not prolong total time on CPB, 
decrease distal coronary visualization, or increase 
duration of crossclamp or sidebiter clamp applica- 
tion. Further, there was no increase in bleeding, 
transfusion requirements, or length of stay for pa- 
tients in the high MAP group. 
Blood pressure targets were achieved uring pe- 
riods of full flow. Flow rates were maintained within 
the prescribed ranges, and all cointerventions were 
equivalent between the two MAP groups, except for 
expected ifferences in the use of vasoactive drugs. 
The total mortality rate at 6 months was 2.8%, 
with most of the mortality occurring in the periop- 
erative period. At 6 months after the operation, 
3.5% had cardiac complications and 4.8% had neu- 
rologic complications. These rates compare favor- 
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Table VII. Postoperative factors in the low and high 
MAP groups 
Low MAP High MAP 
77 ± 250 60 ± 171 Length of intensive care unit stay 
(mean hours) 
Length of hospital stay (mean days) 17 + 25 
Packed red blood cells (mean units) 3.8 +_ 5.4 
Length of intubation (mean hours) 24 +_ 21 
Chest ube drainage at 24 hours 1011 _+ 701 
(mean milliliters) 
13 _+ 14 
4.0 ± 4.7 
32 + 118 
885 ± 500 
ably to other outcome studies of elective CABG. 33 
The rates of cognitive complications reported in 
other trials vary, primarily because the criteria used 
for defining the cognitive deterioration differ among 
these trials. TM 35 
The individual occurrence of outcomes (mortal- 
ity, cardiac, neurologic, cognitive, and functional) all 
favored the high MAP group. In some instances, 
very low complication rates contributed to the lack 
of statistical significance; the trial sample size was 
calculated in advance assuming higher rates of mor- 
tality and morbidity in the control group. When the 
results were analyzed by comparing the outcomes, 
the high MAP group had a significantly lower com- 
bined incidence of cardiac and neurologic morbidity 
and mortality. 
A pragmatic analysis was performed to evaluate 
the relationshi p of achieved MAP to outcomes. This 
analysis confirmed that patients with lower achieved 
MAPs tended to have more cardiac and neurologic 
morbidity and mortality than those maintained at 
high MAPs. 
In conclusion, this study demonstrates that higher 
MAPs can be achieved in a technically safe and 
reliable manner. This elevation of MAP during CPB 
effectively improves outcomes after elective CABG. 
REFERENCES 
1. CASS principal investigators and their associates. 
Myocardial infarction and mortality in the Coronary 
Artery Surgery Study (CASS) randomized trial. N 
Engl J Med 1984;310:750-8. 
2. European Coronary Surgery Study Group. Long term 
results of prospective randomised study of coronary 
artery bypass urgery in stable angina pectoris. Lancet 
1982;2:1173-80. 
3. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of 
the internal-mammary-artery grafton 10 year survival 
and other cardiac events. N Engl J Med 1986;314:1-6. 
4. Mangano DT, Siliciano D, Hollenberg M, et al. 
Postoperative myocardial ischemia: therapeutic trials 
using intensive analgesia following surgery. Anesthe- 
siology 1992;76:342-53. 
5. Slogoff S, Girgis KA, Keats AS. Etiologic factors in 
neuropsychiatric complications associated with car- 
diopulmonary bypass. Anesth Analg 1982;61:903-11. 
6. Shaw PJ, Bates D, Cartlidge NEF, et al. Neurologic 
complications of coronary artery bypass graft surgery: 
six month follow-up study. Br Med J 1986;293:165-7. 
7. Murkin JM. Neurologic dysfunction after CAB or 
valvular surgery. Is the medium the miscreant? 
Anesth Analg 1993;76:213-4. 
8. Shaw P J, Bates D, Cartlidge NEF, et al. Long term 
intellectual dysfunction following coronary bypass 
surgery. Q J Med 1987;239:259-68. 
9. Hessel EA, Johnson DD, Ivey TD, Miller DW. Mem- 
brane versus bubble oxygenator for cardiac opera- 
tions: a prospective randomized study. J THORAC 
CARDIOVASC SURG 1980;80:111-22. 
10. Blauth C, Arnold J, Schulenberg W, et al. Cerebral 
microembolism during cardiopulmonary bypass. J 
THORaC CARDIOVASC Suao 1988;95:668-76. 
11. Stockard JJ, Bickford RG, Schauble JF. Pressure- 
dependent cerebral ischemia during cardiopulmonary 
bypass. Neurology 1973;23:521-9. 
12. Charlson ME, Ales KL, Pompei P, MacKenzie CR: A 
new method of classification of prognostic omorbid- 
ity for longitudinal studies: development and valida- 
tion. J Chronic Dis 1987;40:373-83. 
13. Weissman MM, Sholomskas D, Pottenger M, Prusoff 
BA, I~cke BZ. Assessing depressive symptoms in five 
psychiatric populations: a validation study. Am J 
Epidemiol 1977;106:203-14. 
14. Williams-Russo P, Sharrock NE, Mattis S, Szatronski 
TP, Charlson ME. Cognitive ffects after epidural vs 
general anesthesia:  randomized trial. JAMA 1995; 
274:44-50. 
15. Ammons RB, Ammons CH. The Quick Test (QT): 
provisional manual. Psychoperioperative cognitive as- 
sessment in elderly patients. International Neuropsy- 
chology Society. Psychol Rep 1962;11:111-61. 
16. Stewart AL, Greenfield S, Hays RD, et al. Functional 
status and well-being of patients with chronic condi- 
tions: results from the Medical Outcomes Study. 
JAMA 1989;262:907-13. 
17. Bashein G, Townes BD, Nessly ML, et al. A random- 
ized study of carbon dioxide management during 
hypothermic cardiopulmonary b pass. Anesthesiology 
1990;72:7-15. 
18. Ware J, Kosinski M, Keller SD. SF-36 Physical and 
Mental Component Summary Measures--A User's 
Manual. Boston: New England Medical Center, The 
Health Institute. [In press]. 
19. Campeau L. Letter to the Editor. Circulation 1976; 
54:522. 
20. Slogoff S, Keats AS. Randomized trial of primary 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 5 
Gold et al. 1311 
anesthetic agents on outcome of coronary artery 
bypass operations. Anesthesiology 1989;70:179-88. 
21. Leung JM, Goehner P, O'Kelly B, et al. Isoflurane 
anesthesia and myocardial ischemia: comparative risk 
versus sufentanil anesthesia in patients undergoing 
coronary artery bypass urgery. Anesthesiology 1991; 
74:838-47. 
22. Helman JD, Leung JM, Bellows WH, et al. The risk of 
myocardial ischemia in patients receiving desflurane 
versus sufentanil anesthesia for coronary artery by- 
pass graft surgery. Anesthesiology 1992;77:47-62. 
23. Zaidan JR, Klochany A, Martin WM, Ziegier JS, 
Harless DM, Andrews RB. Effect of thiopental on 
neurol0gic outcome following coronary artery bypass 
grafting. Anesthesiology 1991;74:406-11. 
24. Nussmeier NA, Arlund C, Slogoff S. Neuropsychiatric 
complications after cardiopulmonary b pass: cerebral 
protection by a barbiturate. Anesthesiology 1986;64: 
165-70. 
25. Aris A, Solanes H, Camara ML, Junque C, Escartin 
A, Caralps JM. Arterial line filtration during cardio- 
pulmonary bypass: neurologic, neuropsychologic, and 
hematologic studies. J THORAC CARDIOVASC SURG 
1986;91:526-33. 
26. Pugsley W, Linger L, Paschalis C, Treasure T, Harri- 
son M, Newman S. The impact of microemboli during 
cardiopulmonary b pass on neuropsychological func- 
tioning i Stroke 1994;25:1393-9. 
27. Ellis RJ, Wisniewski A, Potts R, Calhoun C, Loucks P, 
Wells MR. Reduction of flow rate and arterial pres- 
sure at moderate hypothermia does not result in 
cerebral dysfunction. J THOe, AC CARD~OVASC SURO 
1980;79:173-80. 
28. Slogoff S, Reul G J, Keats AS. Role of perfusion 
pressure and flow in major organ dysfunction after 
cardiopulmonary b pass. Ann Thorac Surg 1990;50: 
911-8. 
29. Charlson ME, MacKenzie CR, Gold JP, et al. Pre- 
operative and intra-operative hemodynamic predic- 
tors of post-operative myocardial infarction or isch- 
emia in patients undergoing non-cardiac surgery. Ann 
Surg 1989;210:637-48. 
30. Strangaard S. Autoregulation of cerebral blood flow 
in hypertensive patients. Circulation 1976;53:720-7. 
31. Lassen NA, Christensen MS. Physiology of cerebral 
blood flow. Br J Anesth 1976;48:719-34. 
32. ,A~kins CW. Noncardioplegic myocardial preservation 
for coronary revascularization. J THORAC CARDIOVASC 
SURG 1986;88:174-81. 
33. Mangano DT. Perioperative cardiac morbidity. Anes- 
thesiol0gy 1990;72:153-84. 
34. Williams Russo PG, Mattis S, Szatrowski TP, Shar- 
rock Ni Charlson MD. Incidence of post operative 
cognitive deterioration i cardiac versus non cardiac 
surgica! patients. Clin Res 1995;43:304A. 
35. Newman SP. Neuropsychologic and psychological 
36. 
37. 
changes. In: Smith PL, Taylor KM, eds. Cardiac 
surgery and the brain. London: Edward Arnold, 1993: 
34-54. 
The Coronary Drug Project Research Group. The 
Coronary Drug project. Circulation 1973;47(Suppl): 
I1-50. 
Murray JF, Matthay MA, Luce JM, Flick MR. An 
expanded efinition of adult respiratory distress yn- 
drome. Respir Dis 1988;138:720-3. 
Discussion 
Dr. Randall B. Griepp (New York, N.Y.). The most 
important result of this clinical trial is that a high perfu- 
sion pressure during CABG reduces the prevalence of 
perioperative n urologic omplications from about 7% to 
2%. This conclusion differs from that of other studies in 
the past and, to my knowledge, is the first demonstration 
of a cerebral protective ffect of high physiologic perfu- 
sion pressures during CPB. If these data are applicable to 
all patients undergoing CABG, many surgeons may wish 
to change their perfusion protocols. Therefore, a number 
of questions are appropriate. 
First, was there no downside whatsoever to the high 
perfusion pressure, no problems with cannulation site 
bleeding, no increased incidence of clamp injury to the 
aorta? 
Second, were there any factors other than perfusion 
pressure and development of aortic plaque as determined 
by transesophageal chocardiography t at were predictive 
of stroke? In most contemporary studies age has been a 
powerful predictor of stroke. It would be of interest o 
know if this study is representative of and corresponds to
findings in other studies as well. 
Third, it appears that most of the neurologic ompli- 
cations occurred in the subgroups with severe aortic 
atherosclerosis as assessed by transesophageal echo- 
cardiography. If these subgroups are removed, is there 
any hint of a difference in neurologic outcome in 
the remaining majority of patients? If not, is it neces- 
sary to use high perfusion pressures in the majority of 
patients who do not have a high degree of aortic 
atherosclerosis? 
Fourth, what would you propose as a mechanism of 
protection against neurologic injury by high perfusion 
pressures in the presence of severe aortic plaque? It is 
logical that the brain with intracranial stenotic erebro- 
vascular disease might fare better with a higher perfu- 
sion pressure. However, aortic plaque is thought to 
predispose to cerebral injury caused by atheroembo- 
lism, and how a high perfusion pressure would prevent 
or ameliorate such events is not obvious. Do you have 
an explanation? 
A further clinical point. Although perioperative n uro- 
logic events were much more frequent in the high pressure 
group, there was no long-term difference in functional or 
cognitive status. How important then were the periopera- 
rive events? 
Finally, what is your current clinical practice? Do you 
and your colleagues routinely use a perfusion pressure of 
80 to 100 mm Hg in all patients undergoing CABG? If 
not, in which groups do you not do so? 
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My questions are not meant as criticism of this fine 
article but merely to emphasize the importance of work 
in this area. It may be too late for some members of our 
Association to benefit from it, but by the time I need my 
CABG, I would like to know that the problem of 
perioperative neurologic dysfunction has been elimi- 
nated. 
Dr. Gold. Thank you, Dr. Griepp, for your insightful 
questions. The first question dealt with the complica- 
tions associated with the high mean arterial perfusion 
pressure. There actually were none. As a matter of fact, 
there were slightly shorter crossclamp times and less 
perioperative bleeding. The only difficulty we had was 
convincing the seven-member surgical faculty that high 
pressure CPB was indeed safe. There were no compli- 
cations. 
Factors other than the pressure during the perfusion and 
the echocardiographic grade of the aorta for predicting 
stroke included some standard predictors such as age older 
than 75 years and preexisting neurologic abnormality. 
Indeed, in our study the groups at very low risk, 
meaning patients with minimal or no atherosclerosis on 
transesophageal echocardiography, did not have any of 
the strokes that were detected after the operation. How- 
ever, with our increasing use of echocardiography, we
have noted that the extent of disease in the transverse arch 
and in the ascending arch with and without epicardial and 
epiaortic echocardiography and the extent of disease in 
the descending aorta sometimes i very difficult to mea- 
sure. Sometimes one will just catch the corner of a plaque 
that may be a significantly larger structure when fully 
evaluated. We therefore think that the technique is ben- 
eficial to all Categories of patients undergoing coronary 
surgery. 
Regarding the mechanisms of injury, we and others 
have gathered a wealth of data with the use of transcra- 
nial Doppler echocardiography. The embolic compo- 
nents of atherosclerosis of the aorta are significant. 
However, we believe that atherosclerosis of the aorta, 
and indeed the presence of coronary disease, are mark- 
ers for fixed intercerebral vascular stenoses that are 
better managed with higher perfusion pressures. If you 
allow the perfusion pressure to remain within the 
normal autoregulatory range, you overcome some of 
these stenoses and therefore get better end-organ per- 
fusion, not only of the brain but of the heart, the gut, 
and other organs. 
With regard to clinical status, this has been a bit of a 
hard sell. Even within our own institution, in patients with 
absolutely no visible atherosclerosis of the aorta on trans- 
esophageal echocardiography, we keep the pressure be- 
tween 65 and 75 mm Hg. We do study all of these patients 
during the operation (if not before). In patients with 
moderate or advanced isease of the ascending aorta, we 
would keep the mean perfusion pressure above 80 mm 
Hg. If I were the patient, I would want the perfusion 
pressure to be high. 
Dr. Thomas A. Pfeffer (Los Angeles, Calif.). I have two 
questions. The first concerns the technique of performing 
the proximal anastomoses. Was a partial aortic occluding 
clamp used for all proximal anastomoses or were some 
performed with a single total occlusion clamp with all 
distal and proximal anastomoses performed uring the 
same period of aortic crossclamping? Did the detection 
of aortic atherosclerotic disease affect this technique? 
Were any patients considered candidates for an aortic 
endarterectomy procedure, as advocated by Dr. Kou- 
choukos? 
Second, although maintaining a desired perfusion pres- 
sure is generally easy during CPB, that frequently is not 
the case in the period immediately after discontinuation 
of CPB. The patients are usually vasodilated and hemodi- 
luted and we are dependent on our colleagues in anesthe- 
siology for assistance in maintaining adequate perfusion 
pressure. Were there any differences in these two groups 
of patients, concerning their blood pressure and hemody- 
namics, in the period immediately after discontinuation f 
CPB? Could you comment on the requirement for vaso- 
pressors during this period? 
Dr. Gold. All of these patients underwent creation of a 
proximal anastomosis with the application of a partial 
occlusion clamp. Although we are now studying a single- 
clamp versus a two-clamp rotocol using the same type of 
neurologic and cognitive monitoring that has been pro- 
posed in other institutions, for purposes of this study a 
partial occlusion clamp was always used. 
None of the patients had severe enough disease in the 
ascending aorta to warrant an aortic endarterectomy. 
Perhaps in the patients who did have a stroke, we should 
have considered endarterectomy. Maybe we should recon- 
sider this type of procedure in the future in patients with 
advanced isease. 
In answer to your last question, immediately after 
CPB and in the perioperative period in the intensive 
care unit, there were some minor differences between 
the two groups of patients. Patients treated with more 
vasopressor in the intraoperative period required less 
vasopressor after the operation, required less fluid, had 
less weight gain, had a shorter period ventilatory sup- 
port, and actually were released from the intensive care 
unit slightly (but not statistically) faster. Certainly, 
there was no downside from using high perfusion 
pressure. 
Dr. Watts R. Webb (New Orleans, La.). Did you mea- 
sure cerebral blood flow during these studies? The con- 
ventional studies have usually shown that autoregulation 
of blood flow to the brain ranges from 50 up to 150 mm 
Hg, and, with hypothermia, down to 28 ° C or less; auto- 
regulation may continue down to as low as 20 mm Hg. I 
would like to know both the temperatures that you used 
and the blood flows that you measured uring this period 
of time. 
Dr. Gold. We did not measure cerebral blood flow. The 
only flows that we measured were total systemic blood 
flow during CPB. We used 28 ° C (moderate hypothermia) 
for the major part of the aortic crossclamp interval. 
Although your comments about autoregulation of the 
brain are correct, perhaps in patients with advanced 
atherosclerosis of the cerebrovascular system some alter- 
ation in those numbers needs to be made. If you evaluate 
integrated electroencephalographic cerebral function and 
other measurements of cerebral ischemia, you will see that 
as pressures fall in patients with fixed stenoses, regional 
cerebral perfusion suffers. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 110, Number 5 
Gold et al. 1313 
[ ST depression or elevation >lmm I
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I Pulse >!0/rainy ~ Esmolol 0.1 mg/kg ]
~ '~ ~ ~ " ~  Fentanyl 5 ug/kg 
[ MAP >20% of baseline? I ]Y s I 
I MAP<20% °fbaseline?[ [ YEs [ 
I Nitroglycerin i fusion 0.3-1.0 ug/kg/min I
or 
Nitroglycerin 0.3-1.0 ug/kg/min 
or 
Sodium Nitroprusside 0.5-8.0 ug/kg/min 
titrated to effect 
b Phenylephrine 1.5 ug/kg bolus 
up to 7 ug/kg then continuous 
infusion (20mg/250cc) 1-8 ug/kg/min 
titrated to effect 
Appendix Fig. 1. Management of intraoperative ischemia. 
MAP above target ] ' [ Sodium nitroprasside (50mg/250cc) PRN ] 
MAP below target 
I If not effective, then L [ 
V 
Phenylephrine bolus 0.5 to 1.0 mg 
then 
Phenylcphrine ilffusion 10mg/250cc 
Norepinephrine ilffusion 8mg/250cc 
Melaraminol infusion 200nlg/250cc ]
If not effective, then [ 
Appendix Fig. 2. Management of intraoperative MAP. PRN, As required. 
Appendix 1 
Management of intraoperative ischemia. Before or 
after CPB, ischemia (ST elevation or depression >1 
mm) was managed by a nitroglycerin infusion (0.13 to 1 
b~g/kg per minute) if there were no hemodynamic 
changes. If ischemia occurred with an increase in MAP 
of more than 20%, fentanyl (5/xg/kg), nitroglycerin (0.3 
to 1 txg per minute), or sodium nitroprusside was used. 
For pulse rates greater than 80 beats/rain, esmolol (0.1 
mg/kg) was used. If the MAP was less than 20% of 
baseline, phenylephrine (1.5 #xg/kg) was given to mini- 
mize ischemic electrocardiographic changes (Appendix 
Fig. 1). 
Management of blood pressure on CPB. The method 
for blood pressure management during CPB was as fol- 
lows for both randomization groups (Appendix Fig. 2): for 
MAP above target, sodium nitroprusside (50 rag/200 ml) 
infusions were used as necessary. For MAP below target, 
a phenylephrine bolus (0.5 to 1.0 mg) was given; phe- 
nylephrine infusions (10 mg/250 ml) were given if boluses 
were insufficient. If the patient was unresponsive to phe- 
nylephrine, norepinephrine infusion (8 mg/250 ml) was 
used as a second-line vasopressor. Metaraminol (200 
mg/250 ml) was used as a third-line vasopressor if the first- 
and second-line vasopressors failed. 
Appendix 2. Definitions of cardiac complications 
Postoperative myocardial infarction: New persistent Q 
waves of more than 0.03 msec and greater than 1 mV in 
depth required in two contiguous leads on a standard 
twelve-lead electrocardiogram, in the absence of a new 
conduction abnormality or a marked change in the QRS 
axis. 36 
Pulmonary edema: (1) Rales occupying two thirds of the 
lung fields and a typical x-ray picture for pulmonary 
edema or (2) pulmonary capillary wedge pressure persis- 
tently greater than 25 mm Hg. These findings were 
associated with refractory hypoxemia (arterial oxygen 
tension/inspired oxygen fraction <200). 37 
Adult respiratory distress yndrome: Diffuse interstitial 
pattern on the roentgenogram, a pulmonary capillary 
wedge pressure less than 18 mm Hg, and refractory 
hypoxemia. 
Cardiogenic shock: A syndrome of end-organ hypo- 
perfusion (i.e., urine output < 10 ml/hr for >2 hours) 
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with a systolic blood pressure less than 90 mm Hg or a 
mean blood pressure less than 65 mm Hg and a 
pulmonary capillary wedge pressure greater than 18 
mm Hg in combination with a decline in the cardiac 
index to less than 2.2 L/min per square meter. The 
elevated central venous pressure or right atrial pressure 
in the absence of tamponade constituted evidence of 
right heart failure, if the cardiac output was less than 
2.2 L/rain per square meter, This includes the finding of 
systemic hypotension unresponsive to fluid administra- 
tion, with an elevated pulmonary artery or wedge 
pressure in the setting of a cardiac index less than 1.5 
L/min per square meter and evidence of end-organ 
hypoperfusion. 
Appendix 3. The clinically important differences for 
the neuropsychologic test battery 
Boston Naming 
Controlled Oral Word Association 
Benton Visual Retention Test 
Benton Recognition Test 
Mattis Kovner Verbal Recall 
Mattis Kovner Recognition 
Trail Making A 
Trail Making B 
WAIS-R Digit Span 
Finger Tapping Test 
WAIS-R Digit Symbol 
Decrease >4 
Decrease > 12 
Decrease >2 
Decrease >2 
Decrease >3 
Decrease >0.7 
Increase > 22 
Increase > 84 
Decrease >3 
Decrease >6 
Decrease > 11 
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